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Abstract 
Background: There is a crucial need for effective therapies that are immediately available to counteract COVID-19 disease. Recently, 
ELISA binding cross-reactivity against components of human epidemic coronaviruses with currently available intravenous 
immunoglobulins (IVIG) Gamunex-C and Flebogamma DIF (5% and 10%) have been reported. In this study, the same products were 
tested for neutralization activity against SARS-CoV-2, SARS-CoV and MERS-CoV and their potential as an antiviral therapy. Methods: 
The neutralization capacity of six selected lots of IVIG was assessed against SARS-CoV-2 (two different isolates), SARS-CoV and 
MERS-CoV in cell cultures. Infectivity neutralization was measured by determining the percent reduction in plaque-forming units (PFU) 
and by cytopathic effects for two IVIG lots in one of the SARS-CoV-2 isolates. Neutralization was quantified using the plaque reduction 
neutralization test 50 (PRNT50) in the PFU assay and the half maximal inhibitory concentration (IC50) in the cytopathic/cytotoxic method 
(calculated as the minus log10 dilution which reduced the viral titer by 50%). Results: All IVIG preparations showed neutralization of 
both SARS-CoV-2 isolates, ranging from 79 to 89.5% with PRNT50 titers from 4.5 to >5 for the PFU method and ranging from 47.0%-
64.7% with an IC50 ~1 for the cytopathic method. All IVIG lots produced neutralization of SARS-CoV ranging from 39.5 to 55.1 % and 
PRNT50 values ranging from 2.0 to 3.3. No IVIG preparation showed significant neutralizing activity against MERS-CoV. Conclusion: 
In cell culture neutralization assays, the tested IVIG products contain antibodies with significant cross-neutralization capacity against 
SARS-CoV-2 and SARS-CoV. However, no neutralization capacity was demonstrated against MERS-CoV. These preparations are 
currently available and may be immediately useful for COVID-19 management. 
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Introduction 
The outbreak of the novel Severe Acute Respiratory 
Syndrome Coronavirus 2 (SARS-CoV-2) which causes the 
respiratory disease COVID-19 was declared a pandemic by 
the WHO in March 2020. Most infected patients (80%) have 
mild symptoms. However, about 20% of COVID-19 patients 
can progress to severe pneumonia and to acute respiratory 
distress syndrome (ARDS) which is associated with multi-
organ failure and death 1. The current critical situation 
demands an effective and reliable therapy that is immediately 
available to control the progression of the disease. 
Convalescent plasma or plasma-derived immunoglobulin (IG) 
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(either polyvalent IG prepared from healthy donors or 
hyperimmune IG prepared from donors with high antibody 
titers against a specific antigen) have been historically used as 
a readily available therapeutic option in outbreaks of emerging 
or re-emerging infections 2.  
To date, seven human coronaviruses (HCoV) have been 
identified. Four of them are endemic and globally distributed 
(HCoV-229E, HCoV-NL63, HCoV-OC43 and HCoV-HKU1) 3. 
These viruses typically cause mild symptoms and are 
associated with about 15% of common colds 4 . However, the 
three other human coronaviruses (SARS-CoV, MERS-CoV 
and SARS-CoV-2) are zoonotic epidemic viruses that can 
cause severe respiratory infections and fatalities. Severe acute 
respiratory syndrome coronavirus (SARS-CoV) emerged in 
China in 2002 with the last reported case in 2014. Middle East 
respiratory syndrome coronavirus (MERS-CoV) emerged in 
Saudi Arabia a decade later, in 2012, and led to an outbreak in 
South Korea in 2015. MERS-CoV still emerges sporadically 
in humans from its reservoir in camelids 5-7. More recently 
(December 2019), the novel coronavirus SARS-CoV-2 
emerged in China and because of its extraordinary human-to-
human transmissibility is currently causing an unprecedented 
pandemic 8. Although several therapeutic approaches against 
SARS-CoV-2 are under investigation, therapeutic agents of 
proven efficacy are still lacking. Interestingly, coronaviruses 
share some morphological and functional properties that may 
be associated with cross-reactive immune responses. This 
cross-reactivity may have important therapeutic implications 9. 
SARS-CoV, SARS-CoV-2, and MERS-CoV are classified 
within the family Coronaviridae, genus Betacoronavirus, 
subgenera Sarbecovirus (SARS-CoV, SARS-CoV-2) and 
Merbecovirus (MERS-CoV). The spike protein (S), which is 
exposed on the virion surface, is the main determinant of the 
coronavirus entry into the host cell and is also the major target 
of neutralizing antibodies 10. Spikes are formed by trimers of 
protein S, which is in turn formed by subunit (S1) that 
mediates the binding to the cell receptor and a membrane-
anchored subunit (S2) that mediates the fusion of the virus 
with cell membranes 11. Potent neutralizing antibodies often 
target the receptor interaction site on S1. However, the S1 
subunit shows a higher variability than S2. Antibodies 
targeting S1 are often virus-specific making S2 a better target 
for cross-neutralizing antibodies 12,13.  
The amino-acid sequence identity among the S proteins of 
human betacoronaviruses causing mild (HCoV-OC43 and 
HCoV-HKU1) and severe (SARS-CoV, SARS-CoV-2, and 
MERS-CoV) respiratory infections varies between 22% and 
33% 10. However, the S proteins of SARS-CoV and SARS-
CoV-2 share 77% amino-acid identity 14 and more than 90% 
RNA sequence homology 15. Cross-reactivity in antigenic 
responses has been described among human coronaviruses of 
the same genus, particularly betacoronaviruses. Cross-
reactivity between SARS-CoV, MERS-CoV and other 
endemic human coronaviruses has been reported in some 
neutralization assays 16-18. 
Recently, cross-reactivity in ELISA binding assays against 
antigens of SARS-CoV, SARS-CoV-2, and MERS-CoV has 
been reported with currently available intravenous 
immunoglobulins (IVIG) such as Gamunex-C and 
Flebogamma DIF 19. In this study, the neutralization capacity 
of the IVIG products Gamunex-C and Flebogamma DIF 
against these epidemic human coronaviruses ‒SARS-CoV, 
SARS-CoV-2, and MERS-CoV‒ was evaluated.  
Material and Methods 
Experimental products 
IVIG products used in this study were Flebogamma® DIF 
5% and 10% (Instituto Grifols S.A., Barcelona, Spain) and 
Gamunex®-C 10% (Grifols Therapeutics Inc., Raleigh NC, 
USA), two highly purified (≥ 98%-99%IgG), unmodified 
human immunoglobulins. Each product is manufactured from 
plasma collected from thousands of donors in the US and/or 
several European countries. IgG concentrations in 
Flebogamma DIF products were 50 mg/mL and 100 mg/mL 
(5% and 10%) and in Gamunex-C, the concentration was 100 
mg/mL (10%). To ensure a virus-free product, both IVIG 
manufacturing processes contain dedicated steps with high 
pathogen clearance capacity, such as solvent/detergent 
treatment, heat treatment, caprylate treatment and Planova™ 
nanofiltration down to 20 nm pore size. The plasma used to 
manufacture the IVIG lots tested was collected from March 
2018 to October 2019.  
Study design 
Six different lots of Flebogamma DIF and Gamunex-C were 
tested at several dilutions for cross-reactivity against SARS-
CoV, SARS-CoV-2, and MERS-CoV by: i) ELISA 
techniques; and ii) well-stablished neutralization assays in cell 
cultures. Lots were identified as F1 and F2 for Flebogamma 
5% DIF, F3 and F4 for Flebogamma 10% DIF and G1 and G2 
for Gamunex-C. Each experiment was performed in duplicate.  
Handling of viruses and cell cultures was carried out at the 
Level 3 Biosafety Laboratories in the Centro Nacional de 
Biotecnología - Consejo Superior de Investigaciones 
Científicas (CNB-CSIC; Madrid, Spain) and the Institut de 
Recerca i Tecnologia Agroalimentàries - Centre de Recerca 
en Sanitat Animal (IRTA-CReSA; Barcelona, Spain), 
following the centers’ biohazard safety guidelines and under 
authorizations #A/ES/00/I-8 and #SA-10430-20, respectively. 
Virus strains 
Recombinant SARS-CoV was generated from Urbani strain 
using a previously described reverse genetic technique 20. Two 
different SARS-CoV-2 isolates were tested: a) SARS-CoV-2 
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MAD6 isolated from a COVID-19 patient in Spain; and b) 
SARS-CoV-2 (accession ID EPI_ISL_418268 at GISAID 
repository: http://gisaid.org) isolated from a COVID-19 
patient in Spain. Both stock viruses (a and b) were prepared 
by collecting the supernatant from Vero E6 cells, as previously 
described 21. Recombinant MERS-CoV was generated using a 
previously described reverse genetic system 22 from the 
reference sequence of MERS-CoV isolated from the index 
patient EMC/2012 (GeneBank JX869059) 23.  
Cell lines and cultures 
Huh7 is a well differentiated human hepatocyte-derived 
carcinoma cell line, kindly provided by Dr. Luis Carrasco 
(Centro de Biología Molecular Severo Ochoa - Consejo 
Superior de Investigaciones Científicas [CBMSO-CSIC], 
Madrid, Spain). Huh7 is composed of epithelial-like cells 
susceptible to infection by MERS-CoV 24. 
Vero E6 is a cell line isolated from kidney epithelial cells 
extracted from an African green monkey. Vero E6 is 
composed of epithelial-like cells susceptible to infection by 
SARS-CoV and SARS-CoV-2 25.  
At CNB-CSIC, Vero E6 cell lines were kindly provided by 
Dr. Eric Snjider (University of Leiden Medical Center, The 
Netherlands). Both Huh7 and Vero E6 cell lines were cultured 
in Dulbecco-modified Eagle medium (DMEM) supplemented 
with 25 mM HEPES buffer, 2 mM l-glutamine (Sigma-
Aldrich, St. Louis, MI, USA), 1% nonessential amino-acids 
(Sigma-Aldrich), 10% fetal bovine serum (FBS; 
BioWhittaker, Inc., Walkersville, MD, USA). In the post-
infection semisolid medium, the percentage of FBS was 
reduced to 2%, and DEAE-dextran was added to a final 
concentration of 0.08 mg/mL.  
At IRTA-CReSA, Vero E6 cells were obtained from the 
ATCC (ATCC CRL-1586) and cultured in DMEM (Lonza, 
Basel, Switzerland) supplemented with 5% (FBS (EuroClone, 
Pero, Italy), 100 U/mL penicillin, 100 µg/mL streptomycin, 
and 2 mM glutamine 8 (all ThermoFisher Scientific, Waltham, 
MA, USA). In the post-infection medium, the percentage of 
FBS was reduced to 2%. 
IgG ELISA testing procedures 
Qualitative determination of IgG class antibodies cross-
reactivity against antigens of the tested coronaviruses was 
performed using ELISA techniques. IVIG samples were 
serially diluted using the buffer solutions provided in each IgG 
ELISA kit. The following kits were used for the qualitative 
determination of IgG class antibodies in the experimental 
IVIG lots: SARS Coronavirus IgG ELISA kit (Creative 
Diagnostics, Shirley, NY, USA), against virus lysate; Human 
Anti-SARS-CoV-2 Virus Spike 1 [S1] IgG ELISA Kit (Alpha 
Diagnostic Intl. Inc., San Antonio, TX, USA), against S1 
subunit spike protein; RV-402100-1, Human Anti-MERS-NP 
IgG ELISA Kit (Alpha Diagnostic Intl. Inc.), against N 
protein; RV-402400-1, Human Anti-MERS-RBD IgG ELISA 
Kit (Alpha Diagnostic Intl. Inc.), against receptor-binding 
domain (RBD) of S1 subunit spike protein (S1/RBD); RV-
402300-1, Human Anti-MERS-S2 IgG ELISA Kit (Alpha 
Diagnostic Intl. Inc.), against S2 subunit spike protein; RV-
405200 (formerly RV-404100-1). In all cases the 
determinations were carried out following the manufacturer’s 
instructions. Reactivity was rated as negative if no reaction 
was observed with neat IVIG or positive if the lowest IVIG 
dilution demonstrated reactivity. 
Neutralization assay for SARS-CoV, SARS-CoV-2 (MAD6 
isolate) and MERS-CoV 
IVIG samples were serially diluted (factor 10 dilutions: 
1:102, 1:103, 1:104, and 1:105) in Dulbecco’s Phosphate 
Buffered Saline (PBS; Gibco, Thermo Fisher Scientific, 
Waltham, MA, USA). Samples of each IVIG dilution were 
incubated for 1 h (37℃; 5% CO2) with 300 plaque forming 
units (PFU) of SARS-CoV, SARS-CoV-2 or MERS-CoV. 
Aliquots of 50 µL of each IVIG dilution-virus complex were 
added in duplicate to confluent monolayers of Vero E6 cells 
(for SARS-CoV and SARS-CoV-2) or Huh7 (for MERS-
CoV), seeded in 12-well plates and incubated for 1 h (37°C; 
5% CO2). After this adsorption time, the IgG-virus complex 
inoculum was removed, and a semi-solid overlay was added 
(DMEM 2% FBS + 0.6% agarose). Cells were incubated for 
72 h at 37ºC. The semi-solid medium was removed, and the 
cells were fixed with 10% neutral buffered formaldehyde 
(Sigma-Aldrich) for 1 hour at room temperature and stained 
with 0.2% aqueous gentian violet for 10 min, followed by 
plaque counting. The sensitivity threshold of the technique 
was 20 PFU per mL. 
The neutralization potency of the IVIG products was 
expressed in two ways: 1) percent reduction in PFU calculated 
from the PFU count after neutralization by IVIG relative to 
initial PFU count inoculated onto the cells; and 2) plaque 
reduction neutralization test (PRNT50) value, calculated as the 
–log10 of the reciprocal of the highest IVIG dilution to reduce 
the number of plaques by 50% compared to the number of 
plaques without IVIG.  
Neutralization assay for SARS-CoV-2 (EPI_ISL_418268 
isolate) 
A fixed concentration of a SARS-CoV-2 stock (101.8 TCID 
50/mL, a concentration that achieves 50% cytopathic effect) 
was mixed with decreasing concentrations of the IVIG 
samples (range 1:10 to 1:5120), each mixture was incubated 
for 1 h at 37º C and added to Vero E6 cells. To assess potential 
plasma-induced cytotoxicity, Vero E6 cells were also cultured 
with the same decreasing concentrations of plasma in the 
absence of SARS-CoV-2. Uninfected cells and untreated virus 
infected cells were used as negative and positive infection 
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controls, respectively. Plasma from a COVID-19 positive 
patient with a high half-maximal inhibitory concentration 
(IC50) was included as an active positive control (expressed as 
the –log10 of the reciprocal of the dilution). All the cultures 
were incubated at 37ºC and 5% CO2 for 3 days. 
Cytopathic or cytotoxic effects of the virus or plasma 
samples were measured at 3 days post infection, using the Cell 
Titer-Glo luminescent cell viability assay (Promega, Madison, 
WI, USA). Luminescence was measured in a Fluoroskan 
Ascent FL luminometer (ThermoFisher Scientific). 
Neutralization curves are shown as nonlinear regressions. IC50 
values were determined from the fitted curves as the plasma 
dilutions that produced 50% neutralization. Details of the 
technique are available elsewhere 21. 
Results 
Cross-reactivity studies (ELISA binding assays) 
IVIG products showed consistent reactivity to antigens of 
SARS-CoV (culture lysate) at 10-100 mg/mL IgG, SARS-
CoV-2 (S1 subunit protein) at 100 µg/mL IgG, and MERS-
CoV (N protein, S1 subunit/RHD protein and S2 subunit 
protein) at 50 µg/mL IgG (Table 1).  
Neutralization studies of SARS-CoV 
All the assayed IVIG preparations had neutralizing activity 
against SARS-CoV ranging from 39% to 61% (Figure 1). All 
10% IgG IVIG preparations (F3, F4, G1, and G2) showed 
PRNT50 neutralization titers between 2.0 and 3.3, 
corresponding to 50-61% PFU reduction (Figures 1B, 1C). 
The highest PFU reductions, 59.3% and 61.9% (PRNT50 
neutralization titers of 3.2 and 3.3), were observed with lots 
F4 and G1, respectively, at 1 and 0.1 mg/mL IgG (dilution 
factors 2 and 3). The F1 and F2 lots, (5% IgG) showed a lower 
neutralization capacity with PFU reductions of 39.5% and 
43.3%, respectively (Figure 1A).  
 
Neutralization studies of SARS-CoV-2 
For SARS-CoV-2 MAD6 isolate, all IVIG lots, except F1 
(inconclusive results) showed a significant neutralizing 
activity and reached PRNT50 titers ranging from 4.5 to >5 
(Figure 2). PFU reductions ranging from 78.2% to 82.5% were 
observed with lots F2, F3 and F4 at a dilution factor of 1. Even 
at the highest dilution factor (5 = 0.5 and 1 µg/mL), the PFU 
reduction ranged from 38.5% to 50.9% corresponding to 
PRNT50 titers of 4.5-5.0 (Figures 2A, 2B). For lots G1 and G2, 
the PFU reduction was even higher, ranging from 88.5% -
89.5% at a dilution factor of 1 to 61.7% -62.5% at a dilution 
factor of 5 with PRNT50 titers greater than 5 (Figure 2C). 
For the SARS-CoV-2 EPI_ISL_418268 isolate, F4 and G1 
lots neutralized 58.4% and 64.7%, respectively, TCID50 
counts at a dilution factor of 1 (Figure 3). As shown in Figure 
3, one replicate of F4 product failed to demonstrate 
neutralization. 
Neutralization studies of MERS-CoV 
No IVIG lot showed any significant PFU reduction (i.e., 
>10%) on MERS-CoV even at the lowest dilution factor (10 
mg/mL IgG). 
Discussion 
The results presented here demonstrate, for the first time, 
significant cross-neutralization activity against SARS-CoV 
and especially SARS-CoV-2 in therapeutic IVIG concentrates 
(Flebogamma DIF and Gamunex-C). This neutralizing 
activity correlates with the cross-reactivity to different 
coronavirus antigens observed in ELISA binding assays with 
IVIG, as shown in a previous study 19. The plasma used to 
manufacture the tested IVIG lots was collected prior the 
detection of SARS-CoV-2 in Europe and the USA. Therefore, 
these results should be ascribed to cross-reactivity against 
SARS-CoV-2 by antibodies against endemic human 
coronaviruses in the human population at large. Similar results 
have been reported for SARS-CoV and MERS-CoV. 16-18 
Table 1. Results of IgG reactivity against SARS-CoV, SARS-CoV-2, and MERS-CoV. Two independent assays were performed on each IVIG 






Country of origin  
of the plasma 






N protein S1 subunit/RBD S2 subunit 
F1 5% Germany 50 mg/mL 100 µg/mL 50 µg/mL 50 µg/mL 50 µg/mL 
F2 5% Czech Republic 10 mg/mL 100 µg/mL 50 µg/mL 50 µg/mL 50 µg/mL 
F3 10% USA 100 mg/mL 100 µg/mL 50 µg/mL 50 µg/mL 50 µg/mL 
F4 10% Spain 100 mg/mL 100 µg/mL 50 µg/mL 50 µg/mL 50 µg/mL 
G1 10% USA 100 mg/mL 100 µg/mL 50 µg/mL 50 µg/mL 50 µg/mL 
G2 10% USA 100 mg/mL 100 µg/mL 50 µg/mL 50 µg/mL 50 µg/mL 
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These neutralization studies showed that IVIG products 
contain antibodies with cross-neutralizing capacity against 
SARS-CoV (40-60%) and SARS-CoV-2 (80%-90%), but not 
against MERS-CoV (<10%). These results suggest that the 
cross-neutralizing antibodies target antigenic regions more 
conserved in SARS-CoV and SARS-CoV-2 than in MERS-
CoV.  
 
Figure 2. Cross-neutralization capacity of IVIG against SARS-
CoV-2 (MAD6 isolate). The results were represented as 
percentage of neutralization calculated from reduction of PFU 
counts versus serial dilutions (1:102 – 1:105). The dotted lines 
indicate the PRNT50 values, i.e. the –log10 of the reciprocal of 
the highest IVIG dilution to reduce the number of plaques by 
50%. Neutralization by: A) F1-F2 lots of Flebogamma 5% DIF; B) 
F3-F4 lots of Flebogamma 10% DIF; C) G1-G2 lots of Gamunex-C. 
 
 
No significant differences in the neutralizing capacity were 
observed among IVIG lots regardless the country of origin for 
the plasma. This reinforces the broad applicability of these 
results. Two different neutralization techniques were used for 
SARS-CoV-2 and both techniques showed not only the IVIG 
neutralization capacity, but also the reliability of the results. 
In addition, results obtained with two different SARS-CoV-2  
 
Figure 1. Cross-neutralization capacity of IVIG against SARS-CoV. 
The results were represented as percentage of neutralization 
calculated from reduction of PFU counts versus serial dilutions 
(1:102 – 1:105). The dotted lines indicate the PRNT50 values, i.e. 
the –log10 of the reciprocal of the highest IVIG dilution to reduce 
the number of plaques by 50%. Neutralization by: A) F1-F2 lots 
of Flebogamma 5% DIF; B) F3-F4 lots of Flebogamma 10% DIF; 
C) G1-G2 lots of Gamunex-C. 
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isolates confirm that the neutralization capacity is not  
dependent on the isolate. This was not unexpected since no 
significant sequence differences have been observed among 
SARS-CoV-2 isolates currently circulating throughout the 
world.  
The percentage of SARS-CoV-2 cross-neutralization was 
higher in the PFU reduction technique than in the cytopathic 
effect/cytotoxic technique with very low or negative values in 
some few cases (inconclusive for lot F1 by the PFU study, and 
cytopathic effect in one replicate of lot F4). This suggests that 
the technique used and/or slight variations in methodology 
may significantly influence the nature or magnitude of the 
results. Therefore, further evaluation this cross-neutralizing 
activity should be conducted.  
Cross-neutralization is gaining attention as a protective 
mechanism against viral infection in the context of the 
COVID-19 health emergency. The results of this study are in 
agreement with recent studies that describe cross-
neutralization of SARS-CoV-2 by monoclonal antibodies 
from memory B cells of an individual who was infected with 
SARS-CoV 26. Furthermore, SARS-CoV-2-reactive CD4+ T 
cells have been detected in around half of unexposed 
individuals, suggesting that there is cross-reactive T cell 
recognition between circulating common cold coronaviruses 
and SARS-CoV-2 27. However, the levels of cross-
neutralizing antibodies against SARS-CoV-2 in the sera of 
SARS-CoV patients can be highly variable 28. IVIG products 
are prepared using plasma from thousands of different donors, 
hence containing a broad representation of the state of 
immunity in the population at that time. This is consistent with 
the low rate of variability found among the different lots of 
IVIG products tested.  
Nevertheless, greater variability is expected among 
individuals with respect to infection by a given endemic 
human coronavirus. Therefore, it has been hypothesized that 
the diversity of symptoms observed in SARS-CoV-2-infected 
individuals and even the potential for getting infected may 
depend on pre-existing cross-immunity due to previous 
exposure to other endemic human coronaviruses. In this 
regard, a detailed study of the state of immunity in the general 
population distinguishing those affected and not affected by 
the SARS-CoV-2 may be warranted. 
The higher cross-neutralizing capacity of the tested IVIG 
preparations against SARS-CoV and SARS-CoV-2 than 
MERS-CoV may be explained by higher sequence identity of 
the S proteins of circulating mild human coronaviruses 
(HCoV-OC43 and HCoV-HKU1) and SARS-CoV and SARS-
CoV-2 compared to MERS-CoV (32%-33% vs. 23%-25) 14,15. 
Additionally, differences in specific domains of the S protein 
between SARS-CoV and SARS-CoV-2 might explain higher 
cross-reactivity of the tested IVIG against SARS-CoV-2 
compared to SARS-CoV (80%-90% vs. 40%-60%). The 
absence of cross-neutralization against MERS-CoV despite 
the cross-reactivity observed in ELISA assays suggest that 
these antibodies are not neutralizing. This does not necessarily 
indicate that the antibodies are not functional by another 
mechanism. For example, these non-neutralizing antibodies 
could be labelling the virion for identification by immune cells 
and subsequent destruction 29.  
Despite the limitations of the in vitro nature of this study, the 
clinical implications of the findings are encouraging. 
Although IVIG are considered a therapeutic option for 
hyperinflammation in patients with severe COVID-19 30, the 
results of this study may support the use of high dose IVIG as 
a therapy for COVID-19. Positive results have already been 
reported for IVIG in case studies 31,32. IVIG is being tested in 
an ongoing clinical trial 33. Further studies looking at the 
functionality of these antibodies could improve our 
understanding the human coronavirus acquired immunity. 
This could pave the way for IVIG (and other IgG products 
such as intramuscular or subcutaneous preparations) as a 
potential therapeutic/prophylactic approach to fight future 
epidemics by emerging human coronaviruses. 
In conclusion, under the experimental conditions of this 
study, IVIG (Flebogamma DIF and Gamunex-C) contained 
antibodies with significant neutralization capacity against 
SARS-CoV and SARS-CoV-2, but not against MERS-CoV. 
Additional research is warranted to advance IVIG towards 




Figure 3. Cross-neutralization capacity of IVIG lots (F4: 
Flebogamma 10% DIF; G1: Gamunex-C) against SARS-CoV-2 
(EPI_ISL_418268 isolate): The graphs represent the percent 
neutralization calculated by reduction of cytopathic effect 
versus serial dilutions. 
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